Susan Eylward Sells 11,800 Shares of Imunon (NASDAQ:IMNN) Stock

Imunon, Inc. (NASDAQ:IMNN) General Counsel Susan Eylward sold 11,800 shares of Imunon stock in a transaction on Monday, June 29th. The shares were sold at an average price of $1.75, for a total value of $20,650.00. Following the completion of the transaction, the general counsel directly owned 2,896 shares of the company’s stock, valued at $5,068. This represents a 80.29% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Imunon Trading Down 1.1%

Shares of Imunon stock opened at $1.78 on Wednesday. The company has a 50 day moving average of $2.29 and a 200-day moving average of $2.97. Imunon, Inc. has a 1-year low of $1.70 and a 1-year high of $10.69. The company has a market cap of $7.48 million, a PE ratio of -0.34 and a beta of 1.95.

Imunon (NASDAQ:IMNN) last released its earnings results on Tuesday, May 12th. The company reported ($0.84) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.22) by $0.38. Research analysts forecast that Imunon, Inc. will post -3.46 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on IMNN shares. Maxim Group set a $10.00 target price on shares of Imunon and gave the company a “buy” rating in a report on Friday, April 17th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Imunon in a report on Tuesday, April 21st. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Imunon has an average rating of “Hold” and a consensus target price of $10.00.

Hedge Funds Weigh In On Imunon

Hedge funds have recently bought and sold shares of the company. Armistice Capital LLC bought a new position in Imunon in the 4th quarter valued at $1,017,000. DRW Securities LLC raised its stake in shares of Imunon by 6.9% during the 4th quarter. DRW Securities LLC now owns 58,830 shares of the company’s stock worth $224,000 after purchasing an additional 3,803 shares during the period. Finally, Riverview Capital Advisers LLC boosted its holdings in shares of Imunon by 193.3% in the 3rd quarter. Riverview Capital Advisers LLC now owns 34,364 shares of the company’s stock worth $176,000 after buying an additional 22,649 shares during the last quarter. 4.47% of the stock is owned by hedge funds and other institutional investors.

Imunon Company Profile

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma.